{"name": "Synageva BioPharma",
 "permalink": "synageva",
 "crunchbase_url": "http://www.crunchbase.com/company/synageva",
 "homepage_url": "http://www.synageva.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@synageva.com",
 "phone_number": "781-890-1111",
 "description": "protein therapeutics",
 "created_at": "Wed Apr 15 20:39:32 UTC 2009",
 "updated_at": "Sat Jul 14 01:36:30 UTC 2012",
 "overview": "\u003Cp\u003ESynageva is a biopharmaceutical company dedicated to developing and commercializing novel, next generation and follow on protein therapeutics that leverage the unique competitive advantages of their proprietary Synageva Expression Platform (SEPTM). \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       54],
      "assets/images/resized/0004/1377/41377v1-max-150x150.png"],
     [[203,
       74],
      "assets/images/resized/0004/1377/41377v1-max-250x250.png"],
     [[203,
       74],
      "assets/images/resized/0004/1377/41377v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 Chief Executive Officer",
    "person":
     {"first_name": "Sanj",
      "last_name": "K. Patel",
      "permalink": "sanj-k-patel",
      "image": null}},
   {"is_past": false,
    "title": "Vice President, Corporate Development",
    "person":
     {"first_name": "John",
      "last_name": "C. Taylor",
      "permalink": "john-c-taylor",
      "image": null}},
   {"is_past": false,
    "title": "Senior Vice President, Chief Medical Officer \u0026 Head of Research \u0026 Development",
    "person":
     {"first_name": "Anthony",
      "last_name": "Quinn",
      "permalink": "anthony-quinn",
      "image": null}},
   {"is_past": false,
    "title": "Senior Vice President, Commercial and Business Operations",
    "person":
     {"first_name": "Eric",
      "last_name": "Grinstead",
      "permalink": "eric-grinstead",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$117M",
 "funding_rounds":
  [{"round_code": "f",
    "source_url": "http://www.pehub.com/?p=37242",
    "source_description": "Synageva BioPharma Raises $30 Million",
    "raised_amount": 30000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 4,
    "funded_day": 15,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Baker Brothers Investments",
         "permalink": "baker-brothers-investments",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Tullis Health Investors",
         "permalink": "tullis-health-investors",
         "image":
          {"available_sizes":
            [[[150,
               41],
              "assets/images/resized/0004/6022/46022v2-max-150x150.png"],
             [[250,
               69],
              "assets/images/resized/0004/6022/46022v2-max-250x250.png"],
             [[251,
               70],
              "assets/images/resized/0004/6022/46022v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://www.pehub.com/?p=37242",
    "source_description": "Synageva BioPharma Raises $30 Million",
    "raised_amount": 50000000.0,
    "raised_currency_code": "USD",
    "funded_year": 1960,
    "funded_month": 1,
    "funded_day": 1,
    "investments":
     []},
   {"round_code": "f",
    "source_url": "http://www.altassets.net/private-equity-news/by-region/north-america/unitedstates/article/nz17085.html",
    "source_description": "Synageva attracts additional $12m to venture funding round",
    "raised_amount": 12000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 10,
    "funded_day": 22,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "New Leaf Venture Partners",
         "permalink": "new-leaf-venture-partners-2",
         "image":
          {"available_sizes":
            [[[150,
               39],
              "assets/images/resized/0004/2730/42730v1-max-150x150.png"],
             [[250,
               66],
              "assets/images/resized/0004/2730/42730v1-max-250x250.png"],
             [[257,
               68],
              "assets/images/resized/0004/2730/42730v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Covera Ventures",
         "permalink": "hunt-ventures",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0002/8115/28115v4-max-150x150.jpg"],
             [[245,
               56],
              "assets/images/resized/0002/8115/28115v4-max-250x250.jpg"],
             [[245,
               56],
              "assets/images/resized/0002/8115/28115v4-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Yasuda Enterprise Development",
         "permalink": "yasuda-enterprise-development",
         "image":
          {"available_sizes":
            [[[150,
               96],
              "assets/images/resized/0005/4828/54828v2-max-150x150.png"],
             [[225,
               145],
              "assets/images/resized/0005/4828/54828v2-max-250x250.png"],
             [[225,
               145],
              "assets/images/resized/0005/4828/54828v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Baker Brothers Investments",
         "permalink": "baker-brothers-investments",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Tullis Health Investors",
         "permalink": "tullis-health-investors",
         "image":
          {"available_sizes":
            [[[150,
               41],
              "assets/images/resized/0004/6022/46022v2-max-150x150.png"],
             [[250,
               69],
              "assets/images/resized/0004/6022/46022v2-max-250x250.png"],
             [[251,
               70],
              "assets/images/resized/0004/6022/46022v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2011/03/21/daily5-Synageva-finds-25M-financing-for-enzyme-treatment.html",
    "source_description": "Synageva finds $25M financing for enzyme treatment",
    "raised_amount": 25000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 3,
    "funded_day": 21,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "New Leaf Venture Partners",
         "permalink": "new-leaf-venture-partners-2",
         "image":
          {"available_sizes":
            [[[150,
               39],
              "assets/images/resized/0004/2730/42730v1-max-150x150.png"],
             [[250,
               66],
              "assets/images/resized/0004/2730/42730v1-max-250x250.png"],
             [[257,
               68],
              "assets/images/resized/0004/2730/42730v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Hunt Ventures",
         "permalink": "hunt-ventures-3",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Yasuda Enterprise Development",
         "permalink": "yasuda-enterprise-development",
         "image":
          {"available_sizes":
            [[[150,
               96],
              "assets/images/resized/0005/4828/54828v2-max-150x150.png"],
             [[225,
               145],
              "assets/images/resized/0005/4828/54828v2-max-250x250.png"],
             [[225,
               145],
              "assets/images/resized/0005/4828/54828v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Baker Brothers Investments",
         "permalink": "baker-brothers-investments",
         "image": null},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "60 Hickory Drive ",
    "address2": "",
    "zip_code": "02451",
    "city": "Waltham",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Synageva moves to Lexington",
    "stoned_year": 2010,
    "stoned_month": 9,
    "stoned_day": 15,
    "source_url": "http://www.masshightech.com/stories/2010/09/13/daily26-Synageva-expands-moves-HQ-to-Lexington.html",
    "source_text": null,
    "source_description": "Synageva expands, moves HQ to Lexington",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Synageva BioPharma",
      "permalink": "synageva"}},
   {"description": "has won orphan drug status from the European Medicines Agency (EMA) for its enzyme replacement therapy, SBC-102, to treat Lysosomal Acid Lipase Deficiency",
    "stoned_year": 2010,
    "stoned_month": 11,
    "stoned_day": 9,
    "source_url": "http://www.masshightech.com/stories/2010/11/08/daily22-Synageva-lands-orphan-drug-status-in-Europe.html",
    "source_text": null,
    "source_description": "Synageva lands orphan drug status in Europe",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Synageva BioPharma",
      "permalink": "synageva"}},
   {"description": "landed a $25 million private equity funding to support development of the Lexington biotech\u00e2\u20ac\u2122s enzyme replacement therapy, SBC-102",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 21,
    "source_url": "http://www.masshightech.com/stories/2011/03/21/daily5-Synageva-finds-25M-financing-for-enzyme-treatment.html",
    "source_text": null,
    "source_description": "Synageva finds $25M financing for enzyme treatment",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Synageva BioPharma",
      "permalink": "synageva"}},
   {"description": "Synageva closes $115M public offering",
    "stoned_year": 2012,
    "stoned_month": 7,
    "stoned_day": 13,
    "source_url": "http://www.masshightech.com/stories/2012/07/09/daily56-Synageva-closes-115M-public-offering.html",
    "source_text": "",
    "source_description": "Synageva closes $115M public offering",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Synageva BioPharma",
      "permalink": "synageva"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:GEVA"},
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        96],
       "assets/images/resized/0004/3936/43936v1-max-150x150.jpg"],
      [[250,
        160],
       "assets/images/resized/0004/3936/43936v1-max-250x250.jpg"],
      [[450,
        288],
       "assets/images/resized/0004/3936/43936v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}